RT Journal Article SR Electronic T1 Neurotoxicity—CAR T-cell therapy: what the neurologist needs to know JF Practical Neurology JO Pract Neurol FD BMJ Publishing Group Ltd SP 285 OP 293 DO 10.1136/practneurol-2020-002550 VO 20 IS 4 A1 Lorna Neill A1 Jeremy Rees A1 Claire Roddie YR 2020 UL http://pn.bmj.com/content/20/4/285.abstract AB Chimeric antigen receptor (CAR) T-cell therapy is one of the most innovative therapies for haematological malignancies to emerge in a generation. Clinical studies have shown that a single dose of CAR T-cells can deliver durable clinical remissions for some patients with B-cell cancers where conventional therapies have failed.A significant complication of CAR therapy is the immune effector cell-associated neurotoxicity syndrome (ICANS). This syndrome presents a continuum from mild tremor to cerebral oedema and in a minority of cases, death. Management of ICANS is mainly supportive, with a focus on seizure prevention and attenuation of the immune system, often using corticosteroids. Parallel investigation to exclude other central nervous system pathologies (infection, disease progression) is critical. In this review, we discuss current paradigms around CAR T-cell therapy, with a focus on appropriate investigation and management of ICANS.